Pancreatic cancer is the king of cancers and surgery is currently the only possible curative means. However, even after undergoing radical surgery, many patients are still seen to recur and metastasize within a short period of time in the clinic, and this is a problem that has been troubling clinicians. Therefore, how to determine the risk of postoperative recurrence in patients and how to intervene in those who may be at high risk of recurrence is a topic of interest. Our group (Xu Yong-Feng et al.) assessed the immune status of pancreatic cancer patients by a simple and effective method, and found that the immune status of pancreatic cancer patients directly influenced the long-term outcome after surgery through the analysis of clinical data in a large sample and after a long-term cumulative follow-up study. The study found that: 1. The pancreatic cancer tumor itself can suppress the immune status of patients, and in early stage tumor patients, the immune suppression effect is light, but the more advanced the tumor is, the worse the immune status is. 2. Through long-term follow-up, it was found that the length of survival time is closely related to the immune status of patients. That is, the stronger the immune status, the longer the survival time after surgery. 3. This study also found an interesting phenomenon that although radical pancreatic cancer surgery is very traumatic and recovery is slow, as long as the tumor can be radically removed, the immune status of patients will improve after surgery and even be stronger than the preoperative state. This finding also strongly proves that removal of tumor load can reverse immunosuppression and emphasizes the important role of radical surgery. This finding corrects some prejudices such as “surgery can cause significant damage to the body”. The results of this study have implications for clinical treatment strategies. Our study found that the immune status of the patient’s organism can be assessed by testing, and thus a high-risk group can be screened. Therefore, doctors and patients’ families should pay sufficient attention to this high-risk group. Patients will benefit greatly from timely and effective interventions in these populations. Specifically, the importance of improving the immunity of tumor patients is emphasized in clinical practice. This includes: 1. Removal of tumor load (surgical resection, effective chemotherapy for tumor reduction), both of which can improve the immune status of patients. 2. Through appropriate immune enhancement therapy (e.g. thymidine injection), immune biological therapy, etc. 3. In addition, proper physical exercise, physical and mental rehabilitation and good psychological support are also important ways to improve the body’s immunity against tumors. (This is a point that many people ignore)